{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T19:10:10Z","timestamp":1758568210035,"version":"3.44.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:00:00Z","timestamp":1660176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008799","name":"Gilead Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008799","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.therap.2022.07.010","type":"journal-article","created":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T10:58:38Z","timestamp":1659351518000},"page":"241-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses\u2019 infections"],"prefix":"10.1016","volume":"78","author":[{"given":"Zineb","family":"Ghrieb","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maud","family":"Salmona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Michonneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"De Saisset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souhil","family":"Allaoua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Jacques","family":"Kiladjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00e9r\u00f4me","family":"Le Goff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lina","family":"Benajiba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.therap.2022.07.010_bib0070","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1038\/s41409-021-01462-z","article-title":"Evaluation of prognostic scores for respiratory syncytial virus infection in a French multicentre cohort of allogeneic haematopoietic stem cell transplantation recipients","volume":"56","author":"Houist","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.therap.2022.07.010_bib0075","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1093\/cid\/ciu623","article-title":"Management of respiratory viral infections in hematopoietic cell transplant recipients and patients with hematologic malignancies","volume":"59","author":"Chemaly","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.therap.2022.07.010_bib0080","doi-asserted-by":"crossref","first-page":"27142","DOI":"10.1073\/pnas.1911083116","article-title":"Virus-virus interactions impact the population dynamics of influenza and the common cold","volume":"116","author":"Nickbakhsh","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.therap.2022.07.010_bib0085","unstructured":"Eeuropean Medicines Agency. Guidance on the management of clinical trials during the COVID-19 (coronavirus) pandemic. 2022. https:\/\/ec.europa.eu\/health\/sites\/default\/files\/files\/eudralex\/vol-10\/guidanceclinicaltrials_covid19_en.pdf.[Accessed 25 July 2022 (22 pp.)]."},{"key":"10.1016\/j.therap.2022.07.010_bib0090","unstructured":"Food and Drug Administration. Conduct of Clinical Trials of Medical Products During the COVID-19 Public Health Emergency. Guidance for Industry, Investigators, and Institutional Review Boards. March 2020. Eupdated August 2021. https:\/\/www.fda.gov\/media\/136238\/download.[Accessed 25 July 2022 (39 pp.)]."},{"key":"10.1016\/j.therap.2022.07.010_bib0095","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.therap.2021.02.003","volume":"76","author":"Ghrieb","year":"2021","journal-title":"Therapie"},{"key":"10.1016\/j.therap.2022.07.010_bib0100","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1016\/j.jiph.2021.08.004","article-title":"Changing epidemiology of influenza and other respiratory viruses in the first year of COVID-19 pandemic","volume":"14","author":"Agca","year":"2021","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.therap.2022.07.010_bib0105","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ijid.2020.05.088","article-title":"Does COVID-19 infection impact on the trend of seasonal influenza infection? 11 countries and regions, from 2014 to 2020","volume":"97","author":"Itaya","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.therap.2022.07.010_bib0110","first-page":"100015","article-title":"The impact of the COVID-19 pandemic on influenza, respiratory syncytial virus, and other seasonal respiratory virus circulation in Canada: A population-based study","author":"Groves","year":"2021","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.therap.2022.07.010_bib0115","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S2352-4642(20)30307-2","article-title":"COVID-19 public health measures and respiratory syncytial virus","volume":"4","author":"Britton","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"key":"10.1016\/j.therap.2022.07.010_bib0120","doi-asserted-by":"crossref","first-page":"2100639","DOI":"10.2807\/1560-7917.ES.2021.26.29.2100639","article-title":"Low levels of respiratory syncytial virus activity in Europe during the 2020\/21 season: what can we expect in the coming summer and autumn\/winter?","volume":"26","author":"van Summeren","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.therap.2022.07.010_bib0125","doi-asserted-by":"crossref","first-page":"e2141779","DOI":"10.1001\/jamanetworkopen.2021.41779","article-title":"Estimation of the timing and intensity of reemergence of respiratory syncytial virus following the COVID-19 pandemic in the US","volume":"4","author":"Zheng","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.therap.2022.07.010_bib0130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.therap.2021.05.010","article-title":"COVID-19 vaccines: A perspective from social pharmacology","volume":"76","author":"Montastruc","year":"2021","journal-title":"Therapie"}],"container-title":["Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572200138X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004059572200138X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T18:55:18Z","timestamp":1758567318000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004059572200138X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S004059572200138X"],"URL":"https:\/\/doi.org\/10.1016\/j.therap.2022.07.010","relation":{},"ISSN":["0040-5957"],"issn-type":[{"type":"print","value":"0040-5957"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of the COVID-19 pandemic on antiviral drug development for other community-acquired respiratory viruses\u2019 infections","name":"articletitle","label":"Article Title"},{"value":"Therapies","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.therap.2022.07.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS on behalf of Soci\u00e9t\u00e9 fran\u00e7aise de pharmacologie et de th\u00e9rapeutique.","name":"copyright","label":"Copyright"}]}}